WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2015. 61 scientific abstracts2 will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
Help employers find you! Check out all the jobs and post your resume.
